ストックスクリーナーアプリを入手
2.98
4.93%
0.14
前日終値:
$2.84
開ける：
$2.9
24時間の取引高:
104.57K
Relative Volume:
0.95
時価総額：
$122.01M
収益：
$51.13M
当期純損益:
$-93.80M
株価収益率:
-19.87
EPS:
-0.15
ネットキャッシュフロー:
$-129.10M
1週間 パフォーマンス:
-8.31%
1か月 パフォーマンス:
-17.22%
6か月 パフォーマンス:
-12.35%
1年 パフォーマンス:
-37.39%
1日の値動き範囲:
$2.82
$3.07
1週間の範囲:
$2.75
$3.25
52週間の値動き範囲:
$2.71
$8.49
Repare Therapeutics Inc Stock (RPTX) Company Profile
名前
Repare Therapeutics Inc
セクター
電話
(857) 412-7018
住所
7171 FREDERICK BANTING, SAINT-LAURENT, QC
RPTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| RPTX | 2.99 | 122.01M | 51.13M | -93.80M | -129.10M | -0.15 |
| VRTX | 449.15 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.55 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 598.26 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.12 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.14 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-06-09 | アップグレード | Stifel | Hold → Buy |
| 2023-02-03 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-06 | 開始されました | CapitalOne | Overweight |
| 2022-04-12 | ダウングレード | Stifel | Buy → Hold |
| 2022-03-17 | 再開されました | Goldman | Buy |
| 2021-09-23 | 開始されました | Stifel | Buy |
| 2021-09-13 | 開始されました | H.C. Wainwright | Buy |
| 2021-06-28 | 開始されました | Guggenheim | Buy |
| 2021-03-01 | 開始されました | Berenberg | Buy |
| 2020-10-28 | 開始されました | Northland Capital | Outperform |
| 2020-07-14 | 開始されました | Cowen | Outperform |
| 2020-07-14 | 開始されました | Goldman | Neutral |
| 2020-07-14 | 開始されました | Morgan Stanley | Overweight |
| 2020-07-14 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Repare Therapeutics Inc (RPTX) 最新ニュース
Analysts' Revenue Estimates For Repare Therapeutics Inc. (NASDAQ:RPTX) Are Surging Higher - Simply Wall St
Industry Analysts Just Made A Notable Upgrade To Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts - Yahoo Finance
Repare Therapeutics partners with NCI on cancer drug By Investing.com - Investing.com Australia
Press Release Service: Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib - CRISPR Medicine News
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib - BioSpace
Repare Therapeutics partners with NCI on cancer drug - Investing.com India
Repare Therapeutics Partners with NCI to Advance Breakthrough Cancer Drug Camonsertib | RPTX Stock News - StockTitan
Repare Therapeutics (NASDAQ:RPTX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Repare Therapeutics Reports Q3 2024 Progress and Outlook - TipRanks
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results - CRISPR Medicine News
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Repare Therapeutics (NASDAQ:RPTX) Receives "Buy" Rating from HC Wainwright - MarketBeat
Repare Therapeutics’ individualised anaemia management trial shows promise - Yahoo Finance
Press Release Service: Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial - CRISPR Medicine News
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial - BioSpace
Repare Therapeutics reports progress in cancer trial - Investing.com India
RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug - MSN
Dimensional Fund Advisors LP Sells 27,504 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor - CRISPR Medicine News
Repare Therapeutics doses first subject in Phase I solid tumour trial - Yahoo! Voices
Repare Therapeutics begins trial for novel cancer drug By Investing.com - Investing.com Australia
Marshall Wace LLP Takes Position in Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World
Repare Therapeutics Inc. Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Pol? ATPase Inhibitor - Marketscreener.com
There's No Escaping Repare Therapeutics Inc.'s (NASDAQ:RPTX) Muted Revenues Despite A 35% Share Price Rise - Simply Wall St
XTX Topco Ltd Makes New Investment in Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World
Repare Therapeutics reports promising trial results for cancer drug - Investing.com India
Investing in Repare Therapeutics Inc (RPTX) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
Repare Therapeutics Inc (RPTX)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Press Release Service: Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting - CRISPR Medicine News
Repare Therapeutics reports promising trial results for cancer drug By Investing.com - Investing.com South Africa
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting - BioSpace
Stocks to Watch: CVS Health, PepsiCo, Repare Therapeutics - MarketWatch
Repare Therapeutics Gets Encouraging Early Phase 1 Data for Camonsertib - MarketWatch
Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Purchased by Blue Owl Capital Holdings LP - MarketBeat
Repare Therapeutics Inc. (NASDAQ:RPTX) is definitely on the radar of institutional investors who own 36% of the company - Yahoo Finance
Replimune Group (NASDAQ:REPL) Stock Price Up 3.8% on Analyst Upgrade - MarketBeat
Financial Metrics Unveiled: Replimune Group Inc (REPL)’s Key Ratios in the Spotlight - The Dwinnex
Repare Therapeutics Inc (RPTX) 財務データ
収益
当期純利益
現金流量
EPS
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):